Subscribe

China Meheco Group Co., Ltd. (600056.SS)

CNY9.64 +0.14 (+1.47%)
CN SHH Healthcare Medical - Distribution
Address No. 18 Guangming Zhongjie 100061
Beijing, CN
CEO Huidong Hu
Website meheco.com
IPO 1997-05-15
ISIN CNE000000Q29

Explore sections of this company profile

Description

China Meheco Group Co., Ltd. functions as a pharmaceutical company with a presence across both domestic Chinese and international markets. The enterprise's primary operations involve the import and export of various national Chinese medicines and health-related items, as well as the production and commercial distribution of pharmaceutical and wellness solutions. It also oversees a network of retail pharmacies. The company's extensive product catalog includes bulk pharmaceutical chemicals, such as those from antibiotic fermentation and chemical synthesis, along with finished dosage forms like tablets, injections, and capsules. It supplies a broad range of antibiotics and medications specifically formulated for cardiovascular, cerebrovascular, chronic, and diabetic conditions. Additionally, its offerings encompass antiviral and anti-infectious agents, gastrointestinal remedies, non-steroidal anti-inflammatory drugs, anti-allergic treatments, specialized botanical products, Western medicine preparations, traditional Chinese patent medicines, processed herbal ingredients, medical equipment and supplies, biological products and their raw materials, various chemical raw materials, and nutritional and general healthcare products. Furthermore, China Meheco Group Co., Ltd. engages in the cultivation, processing, warehousing, and transportation of medicinal herbs, including prominent examples such as ginseng, licorice, ephedra, rhubarb, rheum officinale, astragalus membranaceus, scutellaria baicalensis, and fennel. The company, established in 1984, is headquartered in Beijing, China.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY9.64 +0.14 (+1.47%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
26M
Beta
0.16
Float Shares
706.92M
Free Float %
47.3%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.54% +0.71% -4.44% -7.13% -8.16% -4.16% -5.62% -27.74% +6.91% -5.53% +291.30%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
9.64
DCF (Unlevered) 41.29 +328.4%
DCF (Levered) 32.49 +237.0%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2024-11 Change
Strong Buy 4 0
Buy 4 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
2.01
Grey zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
3 / 10
No MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Distribution: +5.6%
    +3.4% Q1'26: -0.9% (vs Q1'25)
  • ✗
    EPS growth Medical - Distribution: +4.9%
    -10.6% Q1'26: +7.9% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Distribution: +37.6%
    +2.5% ★ Q1'26: -18.1% (vs Q1'25)
  • ✗
    EBIT margin Medical - Distribution: +3.0%
    +3.7% ★ Q1'26: +4.2% (vs Q1'25)
  • ✗
    ROIC Medical - Distribution: +5.7%
    +4.7% Q1'26: +6.0% (vs Q1'25)
  • ✗
    Share dilution Medical - Distribution: +0.0%
    +0.0% Q1'26: 0.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×
    4.56× Q1'26: 3.89× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.20) × ERP
WACC = 64% × Ke + 36% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 41.29 Current price: 9.64
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
20.57B
est: 19.02B (+8.2%)
25.95B
est: 25.74B (+0.8%)
30.36B
est: 29.55B (+2.7%)
31.01B
est: 32.29B (-4.0%)
35.28B
est: 32.04B (+10.1%)
39.31B
est: 33.03B (+19.0%)
36.23B
est: 34.10B (+6.2%)
34.15B
est: 19.02B (+79.5%)
35.30B
est: 25.74B (+37.2%)
29.55B
29.55B – 29.55B
+14.8% YoY
32.29B
32.29B – 32.29B
+9.3% YoY
32.04B
32.04B – 32.04B
-0.8% YoY
33.03B
33.03B – 33.03B
+3.1% YoY
34.10B
34.10B – 34.10B
+3.3% YoY
EBITDA
1.13B
est: 938.94M (+20.7%)
1.61B
est: 1.27B (+26.7%)
2.12B
est: 1.46B (+45.6%)
2.09B
est: 1.59B (+31.3%)
2.08B
est: 1.58B (+31.4%)
2.86B
est: 1.63B (+75.7%)
1.59B
est: 1.68B (-5.8%)
1.51B
est: 862.24M (+75.0%)
1.86B
est: 1.17B (+59.5%)
1.34B
1.34B – 1.34B
+14.8% YoY
1.46B
1.46B – 1.46B
+9.3% YoY
1.45B
1.45B – 1.45B
-0.8% YoY
1.50B
1.50B – 1.50B
+3.1% YoY
1.55B
1.55B – 1.55B
+3.3% YoY
EBIT
963.40M
est: 802.75M (+20.0%)
1.46B
est: 1.09B (+34.1%)
1.93B
est: 1.25B (+54.5%)
1.88B
est: 1.36B (+38.1%)
1.85B
est: 1.35B (+37.2%)
2.64B
est: 1.39B (+89.6%)
1.38B
est: 1.44B (-4.4%)
1.19B
est: 688.13M (+73.1%)
1.31B
est: 931.18M (+40.6%)
1.07B
1.07B – 1.07B
+14.8% YoY
1.17B
1.17B – 1.17B
+9.3% YoY
1.16B
1.16B – 1.16B
-0.8% YoY
1.19B
1.19B – 1.19B
+3.1% YoY
1.23B
1.23B – 1.23B
+3.3% YoY
Net Income
614.45M
est: 673.07M (-8.7%)
949.69M
est: 950.84M (-0.1%)
1.31B
est: 1.22B (+7.4%)
1.54B
est: 1.56B (-1.2%)
981.35M
est: 1.28B (-23.5%)
1.31B
est: 1.41B (-7.1%)
647.06M
est: 1.55B (-58.2%)
535.47M
est: 673.15M (-20.5%)
473.23M
est: 950.95M (-50.2%)
1.22B
1.22B – 1.22B
+28.7% YoY
1.56B
1.56B – 1.56B
+27.8% YoY
1.28B
1.28B – 1.28B
-18.0% YoY
1.41B
1.41B – 1.41B
+10.0% YoY
1.55B
1.55B – 1.55B
+9.8% YoY
SGA
1.25B
est: 1.42B (-12.0%)
1.44B
est: 1.92B (-25.1%)
2.08B
est: 2.21B (-5.6%)
4.17B
est: 2.41B (+73.0%)
4.21B
est: 2.39B (+75.8%)
3.31B
est: 2.47B (+34.1%)
3.04B
est: 2.55B (+19.3%)
2.02B
est: 1.30B (+56.0%)
1.82B
est: 1.75B (+3.5%)
2.01B
2.01B – 2.01B
+14.8% YoY
2.20B
2.20B – 2.20B
+9.3% YoY
2.18B
2.18B – 2.18B
-0.8% YoY
2.25B
2.25B – 2.25B
+3.1% YoY
2.33B
2.33B – 2.33B
+3.3% YoY
EPS
0.43
est: 0.45 (-3.7%)
0.66
est: 0.64 (+3.8%)
0.88
est: 0.82 (+7.6%)
1.03
est: 1.05 (-1.5%)
0.66
est: 0.86 (-23.0%)
0.88
est: 0.94 (-6.7%)
0.43
est: 1.04 (-58.2%)
0.36
est: 0.45 (-20.4%)
0.32
est: 0.64 (-49.7%)
0.82
0.82 – 0.82
+28.7% YoY
1.05
1.05 – 1.05
+27.8% YoY
0.86
0.86 – 0.86
-18.0% YoY
0.94
0.94 – 0.94
+10.0% YoY
1.04
1.04 – 1.04
+9.8% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B+ 3/5 5/5 3/5 4/5 2/5 1/5 4/5
2026-05-28 B+ 3/5 5/5 3/5 4/5 2/5 1/5 4/5
2026-05-27 B+ 3/5 5/5 3/5 4/5 2/5 1/5 4/5
2026-05-26 B+ 3/5 5/5 3/5 4/5 2/5 1/5 4/5
2026-05-25 B+ 3/5 5/5 3/5 4/5 2/5 1/5 4/5
2026-05-22 B+ 3/5 5/5 3/5 4/5 2/5 1/5 4/5
2026-05-21 B+ 3/5 5/5 3/5 4/5 2/5 1/5 4/5
2026-05-20 B+ 3/5 5/5 3/5 4/5 2/5 1/5 4/5
2026-05-19 B+ 3/5 5/5 3/5 4/5 2/5 1/5 4/5
2026-05-18 B+ 3/5 5/5 3/5 4/5 2/5 1/5 4/5
2026-05-15 A- 4/5 5/5 3/5 4/5 2/5 2/5 4/5
2026-05-14 A- 4/5 5/5 3/5 4/5 2/5 2/5 4/5
2026-05-13 A- 4/5 5/5 3/5 4/5 2/5 2/5 4/5
2026-05-12 A- 4/5 5/5 3/5 4/5 2/5 2/5 4/5
2026-05-11 A- 4/5 5/5 3/5 4/5 2/5 2/5 4/5
2026-05-08 B+ 3/5 5/5 3/5 3/5 2/5 2/5 4/5
2026-05-07 B+ 3/5 5/5 3/5 3/5 2/5 2/5 4/5
2026-05-06 B+ 3/5 5/5 3/5 3/5 2/5 2/5 4/5
2026-04-30 B+ 3/5 5/5 2/5 4/5 1/5 2/5 4/5
2026-04-29 B+ 3/5 5/5 2/5 4/5 1/5 2/5 4/5
2026-04-28 B+ 3/5 5/5 2/5 4/5 1/5 2/5 4/5
2026-04-27 B+ 3/5 5/5 2/5 4/5 1/5 2/5 4/5
2026-04-24 B+ 3/5 5/5 2/5 4/5 1/5 2/5 4/5
2026-04-23 B+ 3/5 5/5 2/5 4/5 1/5 2/5 4/5
2026-04-22 B+ 3/5 5/5 2/5 4/5 1/5 2/5 4/5
2026-04-21 B+ 3/5 5/5 2/5 4/5 1/5 2/5 4/5
2026-04-20 B+ 3/5 5/5 2/5 4/5 1/5 2/5 4/5
2026-04-17 B+ 3/5 5/5 2/5 4/5 1/5 2/5 4/5
2026-04-16 B+ 3/5 5/5 2/5 4/5 1/5 2/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
1.24B
OE per share TTM
0.83
Owner's Yield
8.39%
Maintenance CapEx ratio
34.17%
Maint CapEx / Avg PPE
7.4%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 25 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Franklin FTSE China ETF FLCH 0.01% 17.7K 0.19%
2 Franklin FTSE China UCITS ETF FLXC.L 0.00% 77.3K 0.19%
3 Dimensional - Emerging Markets Value ETF DFEV 0.00% 66.7K 0.46%
4 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 151.0K 0.39%
5 Schwab Emerging Markets Equity ETF SCHE 0.00% 200.1K 0.06%
6 Vanguard FTSE Emerging Markets Shares ETF VGE.AX 0.00% 16.6K 0.48%
7 Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO 0.00% 37.5K 0.26%
8 Vanguard FTSE Emerging Markets ETF VWO 0.00% 1.85M 0.06%
9 Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L 0.00% 51.6K 0.17%
10 Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L 0.00% 51.6K 0.17%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
156.1K
Shares Outstanding
1.50B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Huibo Zhang Assistant to General Manager — male
Huidong Hu General Manager — female
Jiaqing Hong Deputy General Manager — male
Jing Hua Yuan Board Secretary — male
Xiaohong Ge Chief Accountant — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Distribution